Monopar Therapeutics (MNPR)
↓ Download CSV- Sector Manufacturing
- Incorporated DE
- Fiscal year ends Dec 31
In fiscal 2025, Monopar Therapeutics reported revenue of $0. The company ran a net loss. It held $140.72M in total assets against $2.89M in total liabilities.
Key ratios (FY2025)
-10.0%
Return on equity
| Metric (FY) | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $0 | $0 | — | — | — | — | $0 | $0 | $0 | $0 |
| Operating Income | -$16.70M | -$16.16M | -$8.83M | -$10.54M | -$9.13M | -$6.51M | -$4.32M | -$3.33M | -$16.60M | -$1.19M |
| Net Income | -$13.72M | -$15.59M | -$8.40M | -$10.52M | -$9.10M | -$6.30M | -$4.22M | -$3.23M | -$16.55M | -$1.19M |
| EPS (Diluted) | $-1.85 | $-4.11 | $-3.04 | $-0.83 | — | — | — | — | — | — |
| Total Assets | $140.72M | $60.29M | $7.35M | $13.23M | $20.52M | $16.87M | $13.35M | $7.32M | $9.93M | $2.90M |
| Total Liabilities | $2.89M | $5.25M | $1.76M | $3.14M | $1.58M | $1.18M | $724.2K | $399.6K | $311.9K | $64.5K |
| Shareholders' Equity | $137.83M | $55.04M | $5.59M | $10.09M | $18.94M | $15.69M | $12.63M | $6.92M | $9.62M | $2.83M |
| Cash & Equivalents | $61.83M | $45.82M | $7.27M | $8.19M | $20.30M | $16.74M | $13.21M | $6.89M | $8.98M | $2.07M |
| Operating Cash Flow | -$12.20M | -$6.40M | -$7.86M | -$7.23M | -$7.32M | -$4.66M | -$3.02M | -$2.68M | -$2.63M | -$1.19M |
| Shares Outstanding | 6.69M | 6.10M | 2.98M | 12.95M | 12.60M | 11.45M | 10.59M | 9.29M | 9.29M | 0 |